A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
Clinical trial NCT03760081 · COMPLETED
Trial details
- NCT number
- NCT03760081
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-19
- Primary completion
- 2020-10-16
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.